23andMe Holding Co. (NASDAQ:ME) Insider Sells $18,117.56 in Stock

23andMe Holding Co. (NASDAQ:ME) insider Kathy L. Hibbs sold 38,548 shares of the stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $0.47, for a total transaction of $18,117.56. Following the completion of the transaction, the insider now owns 1,252,315 shares in the company, valued at approximately $588,588.05. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

23andMe Stock Down 4.5 %

Shares of NASDAQ:ME opened at $0.48 on Friday. 23andMe Holding Co. has a twelve month low of $0.35 and a twelve month high of $2.21. The stock has a market capitalization of $233.20 million, a PE ratio of -0.44 and a beta of 1.27. The firm’s 50 day moving average price is $0.54 and its 200-day moving average price is $0.73.

23andMe (NASDAQ:ME) last released its earnings results on Wednesday, February 7th. The company reported ($0.17) EPS for the quarter. 23andMe had a negative return on equity of 52.99% and a negative net margin of 210.48%. The firm had revenue of $44.75 million for the quarter, compared to the consensus estimate of $56.30 million.

Analysts Set New Price Targets

Separately, Citigroup lowered their price objective on shares of 23andMe from $0.85 to $0.47 and set a “neutral” rating on the stock in a research note on Tuesday.

Institutional Investors Weigh In On 23andMe

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mirador Capital Partners LP raised its stake in 23andMe by 11.2% during the 1st quarter. Mirador Capital Partners LP now owns 340,946 shares of the company’s stock worth $181,000 after acquiring an additional 34,321 shares during the period. American International Group Inc. raised its position in shares of 23andMe by 14.9% during the fourth quarter. American International Group Inc. now owns 151,308 shares of the company’s stock valued at $138,000 after buying an additional 19,663 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of 23andMe during the fourth quarter valued at approximately $104,000. Price T Rowe Associates Inc. MD raised its position in shares of 23andMe by 27.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 79,719 shares of the company’s stock valued at $73,000 after buying an additional 16,994 shares during the last quarter. Finally, Barclays PLC raised its position in shares of 23andMe by 400.7% during the fourth quarter. Barclays PLC now owns 472,960 shares of the company’s stock valued at $432,000 after buying an additional 378,500 shares during the last quarter. Institutional investors own 36.10% of the company’s stock.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.